

General information about company	Standalone
Scrip code	540679
NSE Symbol	SMSLIFE
MSEI Symbol	NOTLISTED
ISIN*	INE320X01016
Name of company	SMS Lifesciences India Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Date of board meeting when results were approved	11-11-2023
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-11-2023
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	11-11-2023 16:30
End date and time of board meeting	11-11-2023 17:40
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	6784.06	14240.05
	Other income	33.47	91.77
	<b>Total income</b>	<b>6817.53</b>	<b>14331.82</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	3724.75	8097.57
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-361.58	-226.14
(d)	Employee benefit expense	956.57	1869.1
(e)	Finance costs	247.78	429.79
(f)	Depreciation, depletion and amortisation expense	255.47	508.32
<b>(f)</b>	<b>Other Expenses</b>		
1	Manufacturing Expenses	1152.08	2388
2	Other Expenses	364.99	651.9
10			
	<b>Total other expenses</b>	<b>1517.07</b>	<b>3039.9</b>
	<b>Total expenses</b>	<b>6340.06</b>	<b>13718.54</b>

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	477.47	613.28
4	Exceptional items	0	0
<b>5</b>	<b>Total profit before tax</b>	477.47	613.28
<b>7</b>	<b>Tax expense</b>		
8	Current tax	140	180
9	Deferred tax	25.76	51.52
<b>10</b>	<b>Total tax expenses</b>	165.76	231.52
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	311.71	381.76
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	311.71	381.76

## Financial Results – Ind-AS

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
	<b>Total Amount of items that will not be reclassified to profit and loss</b>		
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	-1.93	-3.7
<b>3 Amount of items that will be reclassified to profit and loss</b>			
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0.56	1.08
5	<b>Total Other comprehensive income</b>	1.37	2.62

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	313.08	384.38
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	10.31	12.63
	Diluted earnings (loss) per share from continuing operations	10.31	12.63
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	10.31	12.63
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	10.31	12.63
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

### Textual Information(1)

1. The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 11th November, 2023 and have been approved by the Board of Directors at its meeting held on 11th November, 2023. The statutory auditors of the Company have carried out a limited review of Standalone financial results for the quarter and half year ended 30th September, 2023 and expressed an unmodified opinion thereon.

2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

4 Figures for the previous period have been reclassified or regrouped wherever necessary to conform to current period's classification.

## Statement of Asset and Liabilities

	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2023
	Date of end of reporting period	30-09-2023
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	<b>Assets</b>	
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	13304.75
	Capital work-in-progress	819.62
	Investment property	
	Goodwill	0
	Other intangible assets	5.99
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	<b>Non-current financial assets</b>	
	Non-current investments	2323.17
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	261.37
	<b>Total non-current financial assets</b>	<b>2584.54</b>
	Deferred tax assets (net)	
	Other non-current assets	457.63
	<b>Total non-current assets</b>	<b>17172.53</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	7334.2
	<b>Current financial asset</b>	
	Current investments	0
	Trade receivables, current	4689.1
	Cash and cash equivalents	100.47
	Bank balance other than cash and cash equivalents	88.63
	Loans, current	0
	Other current financial assets	
	<b>Total current financial assets</b>	<b>4878.2</b>
	Current tax assets (net)	
	Other current assets	4014.69
	<b>Total current assets</b>	<b>16227.09</b>

<b>Statement of Asset and Liabilities</b>		
	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2023
	Date of end of reporting period	30-09-2023
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	<b>Total assets</b>	<b>33399.62</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
<b>Equity attributable to owners of parent</b>		
	Equity share capital	302.33
	Other equity	16439.5
	<b>Total equity attributable to owners of parent</b>	<b>16741.83</b>
	Non controlling interest	
	<b>Total equity</b>	<b>16741.83</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
	Borrowings, non-current	3754.14
	Trade payables, non-current	
	Other non-current financial liabilities	97.55
	<b>Total non-current financial liabilities</b>	<b>3851.69</b>
	Provisions, non-current	390.81
	Deferred tax liabilities (net)	1242.34
	Deferred government grants, Non-current	
	Other non-current liabilities	
	<b>Total non-current liabilities</b>	<b>5484.84</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
	Borrowings, current	5603.18
	Trade payables, current	4194.11
	Other current financial liabilities	726.87
	<b>Total current financial liabilities</b>	<b>10524.16</b>
	Other current liabilities	512.27
	Provisions, current	129.64
	Current tax liabilities (Net)	6.88
	Deferred government grants, Current	
	<b>Total current liabilities</b>	<b>11172.95</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	<b>Total liabilities</b>	<b>16657.79</b>
	<b>Total equity and liabilities</b>	<b>33399.62</b>
<b>Disclosure of notes on assets and liabilities</b>		



## Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2023	01-04-2023
Date of end of reporting period	30-09-2023	30-09-2023
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
<b>1</b>	<b>Segment Revenue (Income)</b>	
	<b>(net sale/income from each segment should be disclosed)</b>	
	<b>Total Segment Revenue</b>	
	<b>Less: Inter segment revenue</b>	
	<b>Revenue from operations</b>	
<b>2</b>	<b>Segment Result</b>	
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>	
	<b>Total Profit before tax</b>	
	<b>i. Finance cost</b>	
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	
	<b>Profit before tax</b>	
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>	
	<b>Segment Asset</b>	
	<b>Total Segment Asset</b>	
	<b>Un-allocable Assets</b>	
	<b>Net Segment Asset</b>	
<b>4</b>	<b>Segment Liabilities</b>	
	<b>Segment Liabilities</b>	
	<b>Total Segment Liabilities</b>	
	<b>Un-allocable Liabilities</b>	
	<b>Net Segment Liabilities</b>	
	<b>Disclosure of notes on segments</b>	

Cash flow statement, indirect		
Particulars		6 months ended (dd-mm-yyyy)
<b>A</b>	Date of start of reporting period	01-04-2023
<b>B</b>	Date of end of reporting period	30-09-2023
<b>C</b>	Whether results are audited or unaudited	Unaudited
<b>D</b>	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
	<b>Statement of cash flows</b>	
	<b>Cash flows from used in operating activities</b>	
	Profit before tax	613.28
	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	1.77
	Adjustments for decrease (increase) in inventories	712.02
	Adjustments for decrease (increase) in trade receivables, current	-137.22
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	16.65
	Adjustments for decrease (increase) in other non-current assets	30.75
	Adjustments for other financial assets, non-current	0.3
	Adjustments for other financial assets, current	-2.61
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-1258.42
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-333.56
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	508.32
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	-27.47
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	263.74
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-2.76
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>-755.97</b>
	<b>Net cash flows from (used in) operations</b>	<b>-142.69</b>
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	-125
	Other inflows (outflows) of cash	297.65
	<b>Net cash flows from (used in) operating activities</b>	<b>279.96</b>

<b>Cash flows from used in investing activities</b>	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property, plant and equipment	1.75
Purchase of property, plant and equipment	696.13
Proceeds from sales of investment property	0
Purchase of investment property	0
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0
Proceeds from sales of intangible assets under development	0
Purchase of intangible assets under development	0
Proceeds from sales of goodwill	0
Purchase of goodwill	0
Proceeds from biological assets other than bearer plants	0
Purchase of biological assets other than bearer plants	0
Proceeds from government grants	0
Proceeds from sales of other long-term assets	0
Purchase of other long-term assets	0
Cash advances and loans made to other parties	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
Dividends received	0
Interest received	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	-2.96
<b>Net cash flows from (used in) investing activities</b>	<b>-697.34</b>
<b>Cash flows from used in financing activities</b>	
Proceeds from changes in ownership interests in subsidiaries	0
Payments from changes in ownership interests in subsidiaries	0
Proceeds from issuing shares	0
Proceeds from issuing other equity instruments	0
Payments to acquire or redeem entity's shares	0
Payments of other equity instruments	0
Proceeds from exercise of stock options	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	1526.42
Repayments of borrowings	685.33
Payments of finance lease liabilities	0
Payments of lease liabilities	26.06
Dividends paid	45.35
Interest paid	266.97
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0

	<b>Net cash flows from (used in) financing activities</b>	502.71
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	85.33
	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	85.33
	Cash and cash equivalents cash flow statement at beginning of period	15.14
	<b>Cash and cash equivalents cash flow statement at end of period</b>	100.47

General information about company	Consolidated
Scrip code	540679
NSE Symbol	SMSLIFE
MSEI Symbol	NOTLISTED
ISIN*	INE320X01016
Name of company	SMS Lifesciences India Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Date of board meeting when results were approved	11-11-2023
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-11-2023
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	11-11-2023 16:30
End date and time of board meeting	11-11-2023 17:40
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	6926.11	16008.08
	Other income	33.59	94.98
	<b>Total income</b>	<b>6959.7</b>	<b>16103.06</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	3574.83	9369.54
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-349.09	-144.48
(d)	Employee benefit expense	1227.88	2396.78
(e)	Finance costs	280.57	498.13
(f)	Depreciation, depletion and amortisation expense	373.43	742.98
<b>(f)</b>	<b>Other Expenses</b>		
1	Manufacturing Expenses	1294.37	2647.68
2	Other Expenses	391.72	698.99
10			
	<b>Total other expenses</b>	<b>1686.09</b>	<b>3346.67</b>
	<b>Total expenses</b>	<b>6793.71</b>	<b>16209.62</b>

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	165.99	-106.56
4	Exceptional items	0	0
<b>5</b>	<b>Total profit before tax</b>	165.99	-106.56
<b>7</b>	<b>Tax expense</b>		
8	Current tax	140	180
9	Deferred tax	70.24	140.46
<b>10</b>	<b>Total tax expenses</b>	210.24	320.46
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	-44.25	-427.02
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	-44.25	-427.02

## Financial Results – Ind-AS

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
	<b>Total Amount of items that will not be reclassified to profit and loss</b>		
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	-0.98	-1.87
<b>3 Amount of items that will be reclassified to profit and loss</b>			
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0.31	0.6
5	<b>Total Other comprehensive income</b>	0.67	1.27



## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	-43.58	-425.75
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent	66.63	-111.53
	Total profit or loss, attributable to non-controlling interests	-110.88	-315.49
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	67.58	-109.72
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-111.17	-316.03
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	2.2	-3.69
	Diluted earnings (loss) per share from continuing operations	2.2	-3.69
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	2.2	-3.69
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	2.2	-3.69
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

1. The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 11th November, 2023 and have been approved by the Board of Directors at its meeting held on 11th November, 2023. The statutory auditors of the Company have carried out a limited review of Consolidated financial results for the quarter and half year ended 30th September, 2023 and expressed an unmodified conclusion thereon.

2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

3 The Consolidated financial results are prepared by applying Ind AS 110- "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary with 60% stake.

4 The loss in Consolidated operations is on account of loss incurred by Subsidiary Company due to delay in Commercialization of pipeline products.

5 The Consolidated entity is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

6 Figures for the previous period have been reclassified or regrouped wherever necessary to conform to current period's classification.

Textual Information(1)

## Statement of Asset and Liabilities

	Particulars	Half year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2023
Date of end of reporting period		30-09-2023
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Consolidated
<b>Assets</b>		
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	21935.25
	Capital work-in-progress	889.24
	Investment property	
	Goodwill	0
	Other intangible assets	5.98
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	<b>Non-current financial assets</b>	
	Non-current investments	3.61
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	304.35
	<b>Total non-current financial assets</b>	<b>307.96</b>
	Deferred tax assets (net)	
	Other non-current assets	461.06
	<b>Total non-current assets</b>	<b>23599.49</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	7891.73
	<b>Current financial asset</b>	
	Current investments	0
	Trade receivables, current	4820.62
	Cash and cash equivalents	107
	Bank balance other than cash and cash equivalents	88.63
	Loans, current	0
	Other current financial assets	
	<b>Total current financial assets</b>	<b>5016.25</b>
	Current tax assets (net)	12.89
	Other current assets	1739.07
	<b>Total current assets</b>	<b>14659.94</b>

<b>Statement of Asset and Liabilities</b>		
	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2023
	Date of end of reporting period	30-09-2023
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	<b>Total assets</b>	<b>38259.43</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
<b>Equity attributable to owners of parent</b>		
	Equity share capital	302.33
	Other equity	16403.83
	<b>Total equity attributable to owners of parent</b>	<b>16706.16</b>
	Non controlling interest	1644.41
	<b>Total equity</b>	<b>18350.57</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
	Borrowings, non-current	4430.92
	Trade payables, non-current	
	Other non-current financial liabilities	97.55
	<b>Total non-current financial liabilities</b>	<b>4528.47</b>
	Provisions, non-current	448.15
	Deferred tax liabilities (net)	1417.2
	Deferred government grants, Non-current	
	Other non-current liabilities	
	<b>Total non-current liabilities</b>	<b>6393.82</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
	Borrowings, current	6050.32
	Trade payables, current	5124.88
	Other current financial liabilities	857.26
	<b>Total current financial liabilities</b>	<b>12032.46</b>
	Other current liabilities	1350.65
	Provisions, current	131.93
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	<b>Total current liabilities</b>	<b>13515.04</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	<b>Total liabilities</b>	<b>19908.86</b>
	<b>Total equity and liabilities</b>	<b>38259.43</b>
<b>Disclosure of notes on assets and liabilities</b>		

## Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2023	01-04-2023
Date of end of reporting period	30-09-2023	30-09-2023
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated	Consolidated
<b>1</b>	<b>Segment Revenue (Income)</b>	
	<b>(net sale/income from each segment should be disclosed)</b>	
	<b>Total Segment Revenue</b>	
	<b>Less: Inter segment revenue</b>	
	<b>Revenue from operations</b>	
<b>2</b>	<b>Segment Result</b>	
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>	
	<b>Total Profit before tax</b>	
	<b>i. Finance cost</b>	
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	
	<b>Profit before tax</b>	
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>	
	<b>Segment Asset</b>	
	<b>Total Segment Asset</b>	
	<b>Un-allocable Assets</b>	
	<b>Net Segment Asset</b>	
<b>4</b>	<b>Segment Liabilities</b>	
	<b>Segment Liabilities</b>	
	<b>Total Segment Liabilities</b>	
	<b>Un-allocable Liabilities</b>	
	<b>Net Segment Liabilities</b>	
	<b>Disclosure of notes on segments</b>	

Cash flow statement, indirect		
Particulars		6 months ended (dd-mm-yyyy)
<b>A</b>	Date of start of reporting period	01-04-2023
<b>B</b>	Date of end of reporting period	30-09-2023
<b>C</b>	Whether results are audited or unaudited	Unaudited
<b>D</b>	Nature of report standalone or consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory.	
	<b>Statement of cash flows</b>	
	<b>Cash flows from used in operating activities</b>	
	Profit before tax	-106.56
	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	2.32
	Adjustments for decrease (increase) in inventories	731.76
	Adjustments for decrease (increase) in trade receivables, current	-214.52
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	51.35
	Adjustments for decrease (increase) in other non-current assets	27.33
	Adjustments for other financial assets, non-current	0.3
	Adjustments for other financial assets, current	-2.61
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-833.96
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	315.79
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	742.98
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	-27.47
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	330.88
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-5.14
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	457.25
	<b>Net cash flows from (used in) operations</b>	350.69
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	-125
	Other inflows (outflows) of cash	437.61
	<b>Net cash flows from (used in) operating activities</b>	913.3

	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	11.02
	Purchase of property, plant and equipment	1387.07
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	232.63
	<b>Net cash flows from (used in) investing activities</b>	<b>-1143.42</b>
	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	1526.43
	Repayments of borrowings	911.57
	Payments of finance lease liabilities	0
	Payments of lease liabilities	26.06
	Dividends paid	45.35
	Interest paid	334.11
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0

	<b>Net cash flows from (used in) financing activities</b>	209.34
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	-20.78
	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0.01
	<b>Net increase (decrease) in cash and cash equivalents</b>	-20.77
	Cash and cash equivalents cash flow statement at beginning of period	127.77
	<b>Cash and cash equivalents cash flow statement at end of period</b>	107